How h.c. was paid
$1.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Angelos M. Stergiou, M.D., Sc.D. h.c.President and Chief Executive Officer | $676,000 | $477,107 | $327,695 | $390,390 | $6,618 | $1,877,810 |
| Dragan Cicic, M. D.Senior Vice President, Chief Development Officer | $451,234 | $185,071 | $143,990 | $193,128 | $18,372 | $991,795 |
| John T. BurnsSenior Vice President, Chief Financial Officer | $429,605 | $185,071 | $143,990 | $185,589 | $15,398 | $959,653 |
What changed and why
- $1.9MCEO total compensation increased to $1,877,810 in fiscal 2025 from $1,189,773 in fiscal 2024.
- $650KBase salary for the CEO rose from $650,000 to $676,000.
- $390KNon-equity incentive compensation for the CEO was $390,390 compared to $339,625 previously.
- $477KStock awards for the CEO totaled $477,107, and option awards were $327,695.
- Short-term incentives were determined based on clinical development and corporate goals.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.